Latest Articles
-
What’s Next For Abbott Stock After A 6% Rise This Year?
Abbott (NYSE: ABT) reported its Q4 results last month, with revenues above and earnings aligning with the street estimates. The company reported revenue of $10.24 billion and earnings of $1.19 on a per-share and adjusted basis, compared to the ...
-
Is Abbott Stock Undervalued At $95?
Abbott (NYSE: ABT) reported its Q3 results last week, with revenues and earnings beating the street estimates. ABT stock is trading at 4.0x sales compared to the last five-year average of 5.4x, and we believe investors will likely be better off...
-
Which Is A Better Pick – Abbott Stock Or Amgen?
Given its better prospects, we believe Abbott stock (NYSE: ABT) is a better healthcare pick than Amgen stock (NASDAQ: AMGN). Both stocks have a similar market capitalization of $150 billion to $160 billion. AMGN trades at a higher valuation m...
-
Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?
We believe Thermo Fisher Scientific stock (NYSE: TMO) is a better pick than its sector peer, Abbott stock (NYSE: ABT), given its better prospects. TMO trades at a slightly higher valuation multiple of 4.9x revenues vs. 4.4x for ABT due to i...
-
Lower Testing Demand To Weigh On Abbott’s Q2?
Abbott (NYSE: ABT) will report its Q2 2023 results on Thursday, July 20. We expect the company to post revenue and earnings in line with the street expectations. Abbott will see a decline in sales given the forex headwinds and lower Covid-19-re...
-
Will Abbott Stock Rebound To Its 2022 Highs?
Abbott stock (NYSE: ABT) currently trades at $106 per share, over 10% below its level in March 2021, and it has the potential for sizable gains. Abbott saw its stock trading at around $109 in late June 2022, just before the Fed started increasi...
-
Which Healthcare Stock Is A Better Pick: Abbott Or This Robotic Products Company?
We believe that Intuitive Surgical stock (NASDAQ: ISRG) is a better pick than its sector peer, Abbott stock (NYSE: ABT). Although ISRG stock trades at a higher valuation of 16.5x trailing revenues, compared to just 4.6x for Abbott, this gap ...
-
What To Expect From Abbott’s Q1?
Abbott (NYSE: ABT) will report its Q1 2023 results on Wednesday, April 19. We expect the company to post revenue and earnings in line with the street expectations. Abbott will see a decline in sales given the forex headwinds and lower Covid-19-...
-
What Is Driving Growth For Abbott Stock?
After a 10% fall year-to-date, at the current levels, Abbott stock (NYSE: ABT) has room for growth, in our view. ABT stock fell from $110 in early January to $99 now. The YTD -10% return for ABT marks an underperformance with the broader S&...
-
Is Abbott Stock A Better Pick Over This Pharmaceuticals Bellwether?
We believe that Abbott stock (NYSE: ABT) is a better pick than its sector peer, Johnson & Johnson stock (NYSE: JNJ). Both stocks are trading at a similar valuation of a little over 4x trailing revenues. Although Abbott has seen better re...
-
Will Abbott Stock Rise After Its Q4 Results?
Abbott (NYSE: ABT) is scheduled to report its Q4 2022 results on Wednesday, January 25. We expect the company to post revenue and earnings slightly above the street expectations. However, supply chain disruptions, forex headwinds, and a decline...
-
Pick Either Abbott Stock Or Its Industry Peer – Both Are Likely To Offer Similar Returns
We believe that Abbott stock (NYSE: ABT) and Medtronic stock (NYSE: MDT) in the medical devices industry will likely give similar returns over the next three years. Although Abbott is trading at a higher valuation of 4.2x trailing revenues, ...
-
This Robotic Surgical Company Is Likely To Offer Better Returns Over Abbott Stock
We believe Intuitive Surgical stock (NASDAQ: ISRG) is currently a better pick than Abbott stock (NYSE: ABT), given its better prospects. Although Abbott is trading at a comparatively lower valuation of 4.1x trailing revenues vs. 15.2x for I...
-
Will Abbott Stock Rise After Its Q3 Results?
Abbott (NYSE: ABT) is scheduled to report its Q3 2022 results on Wednesday, October 19. We expect the company to likely post revenue and earnings slightly below the street expectations. Supply chain disruptions, forex headwinds, and a decline i...
-
This CGM Device Maker Is Likely To Outperform Abbott Stock
We believe DexCom stock (NASDAQ: DXCM) is currently a better pick than Abbott stock (NYSE: ABT), given its better prospects. Although Abbott is trading at a comparatively lower valuation of 3.8x trailing revenues vs. 12.3x for DexCom, this ...
